{"id":"W4385705955","doi":"10.1097/01.hs9.0000971156.02746.02","title":"P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Refractory (planetary science); Oncology; Lymphoma; Cohort; Phases of clinical research; Cancer; Chemotherapy; Gastroenterology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003058072,0.0002788203,0.0006549616,0.0002008398,0.00005845805,0.00003558185,0.0002560974,0.0001604887,0.0001312539],"category_scores_gemma":[0.00006870618,0.0001935954,0.00001956195,0.001490977,0.0001070117,0.0003568556,0.00008027702,0.0002173161,0.000009285352],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003143297,"about_ca_system_score_gemma":0.0003678965,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002496344,"about_ca_topic_score_gemma":0.004108593,"domain_scores_codex":[0.9975358,0.0002290733,0.0006892326,0.0006267405,0.0005919909,0.0003271154],"domain_scores_gemma":[0.9986461,0.0001234295,0.0003223924,0.0006177736,0.0001854277,0.0001048794],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6658499,0.07044934,0.191811,0.00008809666,0.0005025156,0.0009623797,0.008608941,0.00001910473,0.003896383,0.00001161461,0.002436792,0.05536396],"study_design_scores_gemma":[0.331441,0.02626557,0.636336,0.0005040986,0.00006589865,0.00000330012,0.003753576,0.000528492,0.0005554691,0.000007322978,0.0003007763,0.0002384504],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970204,0.00003147799,0.000003399783,0.0002094745,0.00007603896,0.002068717,0.0001455605,0.00007399082,0.0003709754],"genre_scores_gemma":[0.9978681,0.00002264205,0.0001762275,0.0001183389,0.00001749061,0.00007385454,0.00125671,0.00005926804,0.0004073411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.444525,"threshold_uncertainty_score":0.7894592,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03312883533950021,"score_gpt":0.3242228969276194,"score_spread":0.2910940615881191,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}